Seleziona una pagina

Reshaping biopsy and needle-based therapy through
AI-powered robotics.


Prostate cancer is the second most common cancer in men.

In Europe, around 1 million prostate biopsies are carried out each year. Biopsy is still affected by diagnostic errors between 30% and 50%. The main sources of  error are target detection and  needle insertion: both operator dependent! We aim to radically improve the clinical outcome in needle based prostate biopsy procedures by using AI and robotics, turning an operator-dependent procedure into a safe, accurate and repeatable robot-assisted procedure.

Our research

Target Identification and planning
needle positioning
biopsy execution

Needleye Features

The following features represent a competitive advantage compared to other similar devices in the market, moreover we adhere to the international guidelines towards transsperineal biopsy. 

Early detection of lesions
real-time lesion target positioning
real-time needle control
real-time trajectory planning
Smart fusion technology
predictive trajectory planning
ambulatory use